


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of Formula I, and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof:



wherein

R¹ and R² are independently selected from the group consisting of OH, OC₁₋₄alkyl, and halo;

R³ is C₁₋₄alkyl;

R⁴ is selected from the group consisting of ~~C₁₋₆alkyl~~, aryl and heteroaryl with both aryl and heteroaryl being unsubstituted or substituted with 1-5 groups independently selected from C₁₋₄alkyl, hydroxy-substituted C₁₋₆alkyl, OC₁₋₄alkyl, OH, CF₃, OCF₃, halo, SH,

SC₁₋₄alkyl, NH₂, nitro, NHC₁₋₄alkyl, N(C₁₋₄alkyl)(C₁₋₄alkyl), CN, C(O)OH, C(O)OC₁₋₄alkyl, C(O)NHC₁₋₄alkyl, CH=N-OC₁₋₄alkyl, NHC(O)C₁₋₄alkyl, OC(O)C₁₋₄alkyl, SOC₁₋₄alkyl, SO₂C₁₋₄alkyl, SO₂NHC₁₋₄alkyl and SO₂NH₂;

R⁵ are either both H or together form =CH₂;

R⁶ and R⁷ are independently H, C₁₋₄alkyl or are taken together to form a ~~C₃₋₆cycloalkyl~~ C₃₋₆cycloalkyl ring;

x is 0-2; and

---- represents a single or a double bond.

2. (Original) The compound according to claim 1, wherein R¹ and R² are independently selected from the group consisting OH, OCH₃, and fluoro.

3. (Original) The compound according to claim 2, wherein R¹ and R² are both OH.

4. (Original) The compound according to claim 1, wherein R³ is CH₃.

5. (Currently amended) The compound according ~~to claim~~ to claim 1, wherein R⁴ is selected from the group consisting of

unsubstituted and substituted phenyl, pyridyl, thienyl, furanyl and pyrrolo.

6. (Original) The compound according to claim 5, wherein R⁴ is selected from unsubstituted or substituted phenyl.

7. (Original) The compound according to claim 1, wherein both aryl and heteroaryl are either unsubstituted or substituted with 1-3 groups independently selected from C₁₋₄alkyl, hydroxy-substituted C₁₋₆alkyl, OC₁₋₄alkyl, OH, CF₃, OCF₃, halo, SH, SC₁₋₄alkyl, NH₂, NHC₁₋₄alkyl, N(C₁₋₄alkyl)(C₁₋₄alkyl), CN, C(O)OH, C(O)OC₁₋₄alkyl, CH=N-OC₁₋₄alkyl, C(O)NHC₁₋₄alkyl, NHC(O)C₁₋₄alkyl, OC(O)C₁₋₄alkyl, SOC₁₋₄alkyl, SO₂C₁₋₄alkyl, SO₂NHC₁₋₄alkyl and SO₂NH₂.

8. (Original) The compound according to claim 7, wherein both aryl and heteroaryl are either unsubstituted or substituted with 1-2 groups independently selected from methyl, 3-hydroxy-3-pentyl, methoxy, OH, CF₃, OCF₃, halo, NH₂, NMe₂ and CH=N-OMe.

9. (Original) The compound according to claim 8, wherein both aryl and heteroaryl are either unsubstituted or substituted with 1-2 groups independently selected from methyl, 3-hydroxy-3-pentyl, Cl, F and CH=N-OMe.

10. (Currently amended) The compound according to claim 6, wherein R⁴ is selected from the group consisting of phenyl, 4-chlorophenyl, ~~3,4-dichloropheny~~ 3,4-dichlorophenyl, 4-fluorophenyl, 4-methylphenyl, 3,4-difluorophenyl, 4-(3-hydroxy-3-pentyl)phenyl, 4-(CH=N-OMe)phenyl, 4-methoxyphenyl, ~~4-trifluormethylpheny~~ 4-trifluoromethylphenyl and ~~4-ntiophenyl~~ 4-nitrophenyl.

11. (Withdrawn-Currently Amended) The compound according to claim 10, wherein R⁴ is selected from the group consisting of 4-chlorophenyl, ~~3,4-dichloropheny~~ 3,4-dichlorophenyl, 4-(3-hydroxy-3-pentyl)phenyl, 4-fluorophenyl and 4-methylphenyl.


12. (Currently amended) The compound according to claim 1, wherein R⁶ and R⁷ are independently H, methyl or are taken together to form a ~~C₃₋₄eyloalkyl~~ C₃₋₄cycloalkyl ring.

13. (Currently amended) The compound according to claim 12, wherein R⁶ and R⁷ are both H or are taken together to form a ~~C₃₋₄eyloalkyl~~ C₃₋₄cycloalkyl ring.

14. (Original) The compound according to claim 1, wherein x is 2.

15. (Original) The compound according to claim 1, wherein --- represents a single bond.

16. (Currently amended) A compound of Formula I, and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof:



wherein

R¹ and R² are independently selected from the group consisting of OH, OC₁₋₄alkyl, and halo;

R³ is C₁₋₄alkyl;

R⁴ is selected from the group consisting of aryl and heteroaryl with both aryl and heteroaryl being unsubstituted or substituted with 1-5 groups independently selected from C₁₋₄alkyl, hydroxy-substituted C₁₋₆alkyl, OC₁₋₄alkyl; OH, CF₃, OCF₃, halo, SH, SC₁₋₄alkyl, NH₂, nitro, NHC₁₋₄alkyl, N(C₁₋₄alkyl)(C₁₋₄alkyl), CN, C(O)OH, C(O)OC₁₋₄alkyl, C(O)NHC₁₋₄alkyl, NHC(O)C₁₋₄alkyl, OC(O)C₁₋₄alkyl, SOC₁₋₄alkyl, SO₂C₁₋₄alkyl, SO₂NHC₁₋₄alkyl and SO₂NH₂;


R⁵ are either both H or together form =CH₂;

R⁶ and R⁷ are independently H, C₁₋₄alkyl or are taken together to form a ~~C₃₋₆cycloalkyl~~ C₃₋₆cycloalkyl ring;

x is 0-2; and

---- represents a single or a double bond.

17. (Currently amended) A compound of Formula I, and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof:



wherein

R¹ and R² are independently selected from the group consisting of OH, OC₁₋₄alkyl, and halo;

R³ is C₁₋₄alkyl;

R⁴ is selected from the group consisting of ~~C₁₋₆alkyl~~, aryl and heteroaryl with both aryl and heteroaryl being unsubstituted or substituted with 1-5 groups independently selected from C₁₋₄alkyl, hydroxy-substituted C₁₋₆alkyl, OC₁₋₄alkyl, OH, CF₃, OCF₃, halo, SH, SC₁₋₄alkyl, NH₂, nitro, NHC₁₋₄alkyl, N(C₁₋₄alkyl)(C₁₋₄alkyl), CN,


C(O)OH, C(O)OC₁₋₄alkyl, C(O)NHC₁₋₄alkyl, CH=N-OC₁₋₄alkyl,
NHC(O)C₁₋₄alkyl, OC(O)C₁₋₄alkyl, SOC₁₋₄alkyl, SO₂C₁₋₄alkyl, SO₂NHC₁₋₄alkyl and SO₂NH₂;




R⁵ are either both H or together form =CH₂;







x is 0-2; and







---- represents a single or a double bond.




18. (Currently amended) The compound according to claim 1 ~~that~~
~~is~~ selected from the group consisting of:











and pharmaceutically acceptable salts, hydrates, solvates and
prodrugs thereof.

19. (Currently amended) The compound according to claim \pm 18, selected from the group consisting of I(a), I(e), I(g), I(i), I(m), I(o), I(q), I(u), I(cc), I(ee), I(jj), I(ll), I(nn) and I(oo).

20. (Currently amended) The compound according to claim \pm 18, selected from the group consisting of I(a), I(e), I(g), I(i), I(u), I(cc), I(ee), I(jj), I(nn) and I(oo).

21-22. (Canceled herein).

23. (Original) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

24. (Withdrawn) A method for treating diseases which benefit from a modulation of the levels of $1\alpha,25$ -dihydroxy vitamin D₃, or analogs thereof, comprising administering an effective amount of a compound according to claim 1 to a cell or animal in need thereof.

25. (Withdrawn) A method for treating diseases which benefit from an increase in the levels of $1\alpha,25$ -dihydroxy vitamin D₃, or

analogues thereof, comprising administering an effective amount of a compound according to claim 1 to a cell or animal in need thereof.

26. (Withdrawn) A method for treating diseases which benefit from an inhibition of the catabolism of $1\alpha,25$ -dihydroxy vitamin D_3 , or analogues thereof, comprising administering an effective amount of a compound according to claim 1 to a cell or animal in need thereof.

27. (Withdrawn) The method according to claim 26, wherein the disease is selected from the group consisting of cancer, dermatological disorders, parathyroid disorders, autoimmune disorders and bone disorders.

28. (Withdrawn) The method according to claim 27, wherein the disease is selected from the group consisting of cancer, psoriasis, hyperparathyroidism, secondary hyperparathyroidism and osteoporosis.

29. (Withdrawn) A method of inhibiting cell proliferation and/or for promoting cell differentiation comprising

administering an effective amount of a compound according to claim 1 to a cell or animal in need thereof.

30. (Withdrawn) The method according to claim 29, wherein the cell is a cancer cell.

31. (Withdrawn) The method according to claim 30, wherein the cancer is selected from breast cancer, lung cancer, prostate cancer, colon cancer, colorectal cancer, kidney cancer, head and neck cancer, pancreatic cancer, Kaposi's sarcoma and leukemia.

32. (Withdrawn) The method according to claim 29, wherein the cell is a skin cell.

33. (Withdrawn) The method according to claim 32, wherein the cell is a keratinocyte.

34. (Withdrawn) A method of inhibiting CYP24 activity in a cell by administering an effective amount of a compound according to claim 1 to the cell.

35. (Withdrawn) A method of treating a disease which benefits from an inhibition of CYP24 activity comprising administering an

effective amount of a compound according to claim 1 to an animal or cell in need thereof.

36-45. (Canceled herein).

46. (Withdrawn) A method for increasing the efficacy of a vitamin D receptor agonist comprising co-administering an effective amount of a compound according to claim 1 and an effective amount of a vitamin D receptor agonist to an animal or cell in need thereof.

47. (Withdrawn) A method of treating diseases comprising co-administering an effective amount of a compound according to claim 1 and an effective amount of a vitamin D receptor agonist to an animal or cell in need thereof.

48. (Withdrawn) The method according to claim 47, wherein the vitamin D receptor agonist is $1\alpha,25$ -dihydroxy vitamin D₃ (calcitriol), or an analog thereof.

49. (Withdrawn) The method according to claim 47, wherein the disease is selected from the group consisting of cancer,

dermatological disorders, parathyroid disorders, autoimmune disorders and bone disorders.

50. (Withdrawn) The method according to claim 49, wherein the disease is selected from the group consisting of cancer, psoriasis, hyperparathyroidism, secondary hyperparathyroidism and osteoporosis.

51. (Withdrawn) The method according to claim 50, wherein the disease is cancer.

52. (Withdrawn) The method according to claim 51, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, prostate cancer, colon cancer, colorectal cancer, kidney cancer, head and neck cancer, pancreatic cancer, Kaposi's sarcoma and leukemia.

53-59. (Canceled herein).

60. (Withdrawn) A method of treating cancer, dermatological disorders, parathyroid disorders, autoimmune disorders or bone disorders comprising administering an effective amount of a compound according to claim 1 in combination with one or more

therapies or therapeutics to treat cancer, dermatological disorders, parathyroid disorders, autoimmune disorders or bone disorders, to an animal or cell in need thereof.

61. (Withdrawn) A method of treating cancer comprising administering an effective amount of a compound according to claim 1 in combination with one or more therapies or therapeutics to treat cancer.

62. (Withdrawn) The method according to claim 61, wherein the one or more therapies or therapeutics to treat cancer are selected from the group consisting of surgery, radiation, chemotherapy and biotherapy.

63. (Withdrawn) A method of treating psoriasis comprising administering an effective amount of a compound according to claim 1 in combination with one or more therapies or therapeutics to treat psoriasis.

64. (Withdrawn) The method according to claim 63, wherein the one or more therapies or therapeutics to treat psoriasis are selected from the group consisting of ultraviolet B radiation, chemotherapy and biotherapy.

Serial No. 10/612,302
Reply to Office Action dated October 25, 2005
Page 19

65-67. (Canceled herein).